Retraction

A novel, orally active alpha 4 integrin antagonist, AJM300 prevents the development of experimental colitis induced by adoptive transfer of IL-10 deficient CD4(+) T cells in mice

Retraction Details

Nature of Retraction:

Retraction

Retraction Notice:
10.1124/jpet.112.193946
Additional Notes:

affiliations taken from related articles by authors

Citations (3)

3
Total Citations
3
Post-Retraction
(100.0%)
0
Pre-Retraction
0
Same Day
Post-Retraction Citation Analysis
0 Within 30 days
2 Within 1 year
1 After 2+ years
1263 Days since retraction (latest)
Paper citing A novel, orally active alpha 4 integrin antagonist...
Unknown Authors
Unknown Journal
Published: Jan 2016
1263 days after retraction
Paper citing A novel, orally active alpha 4 integrin antagonist...
Unknown Authors
Unknown Journal
Published: Oct 2012
62 days after retraction
Paper citing A novel, orally active alpha 4 integrin antagonist...
Unknown Authors
Unknown Journal
Published: Oct 2012
61 days after retraction
Quick Stats
Total Citations: 3
Years Since Retraction: 13.3 years
Open Access: Yes
Last Checked: Never
Related Papers
Resveratrol Protects Murine Chondrogenic ATDC5 Cells Agains…
Cellular Physiology and Biochemistry • 26 citations
Development of Angiotensin IV Analogs as Hepatocyte Growth …
The Journal of Pharmacology and Experimental Therapeutics • 28 citations
Evaluation of Metabolically Stabilized Angiotensin IV Analo…
The Journal of Pharmacology and Experimental Therapeutics • 53 citations
The Procognitive and Synaptogenic Effects of Angiotensin IV…
The Journal of Pharmacology and Experimental Therapeutics • 32 citations
Mimics of the Dimerization Domain of Hepatocyte Growth Fact…
The Journal of Pharmacology and Experimental Therapeutics • 21 citations